Bilimsel çalışmalar

Doç. Dr. Seray Saray

42 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062353 PMID 41899277 Açık erişimli tam metinKaynak: ORCID

  2. Stage 4A Lung Adenocarcinoma with Rare EGFR Exon 21 L861Q and Exon 18 G719A Co-Mutations Showing Complete PET-CT Response to Osimertinib: A Case Report

    Case Reports in Oncology, 2026

    DOI 10.1159/000551796 PMID 42257038 Açık erişimli tam metinKaynak: ORCID

  3. Radiotherapy improves outcomes in patients with NSCLC receiving nivolumab

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15805-w PMID 41749167 Açık erişimli tam metinKaynak: ORCID

  4. Analysis of prognostic factors in metastatic colon cancer

    Turkish Journal of Clinics and Laboratory, 2026

    DOI 10.18663/tjcl.1803902 Açık erişimli tam metinKaynak: ORCID

  5. Do Inflammatory Indices Predict Neoadjuvant Chemotherapy Response in Hormone Receptor-positive, HER2-negative Breast Cancer?

    Namık Kemal Tıp Dergisi, 2026

    DOI 10.4274/nkmj.galenos.2025.81594 Açık erişimli tam metinKaynak: OpenAlex

  6. Low baseline breast TLG and axillary MTV independently predict pathological complete response in HR-positive/HER2-negative breast cancer

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-17192-8 Açık erişimli tam metinKaynak: OpenAlex

  7. The ımpact of the novel tumor marker ındex (TMI) on survival and prognosis in metastatic gastric cancer

    American Journal of Cancer Research, 2026

    DOI 10.62347/jgid2940 Kaynak: OpenAlex

  8. Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study

    Anti-Cancer Drugs, 2025

    DOI 10.1097/cad.0000000000001717 PMID 40162996 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  9. Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study

    Therapeutic Advances in Medical Oncology, 2025

    DOI 10.1177/17588359251368069 PMID 40900677 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  10. FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

    Cancers, 2025

    DOI 10.3390/cancers17172730 PMID 40940827 Açık erişimli tam metinKaynak: ORCID

  11. FOLFIRINOX: The best adjuvant treatment for ampullary adenocarcinoma?

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e16261 Kaynak: ORCID

  12. Expression of gamma-aminobutyric acid type A receptor subunit π and minichromosome maintenance-3 in breast cancer patients treated with neoadjuvant chemotherapy: a target molecule or a proliferation marker?

    Revista da Associação Médica Brasileira, 2025

    DOI 10.1590/1806-9282.20250507 PMID 41124552 Açık erişimli tam metinKaynak: ORCID

  13. Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14165868 PMID 40869694 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  14. Comparison of frontline FOLFIRINOX with fluorouracil-based and gemcitabine-basedchemotherapies in metastatic ampullary adenocarcinoma: A multicenter cohort study.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e16264 Açık erişimli tam metinKaynak: OpenAlex

  15. Androgen Receptor: Clinical Importance in Breast Cancer Patients Receiving CDK 4/6 Inhibitor Treatment

    Medicina, 2025

    DOI 10.3390/medicina61081464 PMID 40870508 Açık erişimli tam metinKaynak: ORCID

  16. Androgen Receptor: Clinical Importance in Breast Cancer Patients Receiving CDK 4/6 Inhibitor Treatment

    Medicina (Kaunas, Lithuania), 2025

    Kaynak: ORCID

  17. Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

    Journal of clinical medicine, 2025

    Kaynak: ORCID

  18. Case report: Drug-induced vitiligo during treatment with BRAF/MEK inhibitors in a patient with metastatic conjunctival melanoma

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2025

    DOI 10.1177/10781552231189819 PMID 37499639 1 atıf (Europe PMC) Kaynak: ORCID

  19. Do Inflammatory Indices Have Prognostic Value in Metastatic Breast Cancer Patients Receiving CDK 4/6 Inhibitor Therapy?

    The Eurasian Journal of Medical Investigation, 2025

    DOI 10.14744/ejmi.2025.85675 1 atıf (OpenAlex) Kaynak: ORCID

  20. Predictive Factors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing 177Lu-PSMA-617 Radioligand Treatment

    Journal of the College of Physicians and Surgeons Pakistan, 2025

    DOI 10.29271/jcpsp.2025.10.1261 PMID 41058281 Açık erişimli tam metinKaynak: ORCID

  21. Spectrum of BRCA1 and BRCA2 Variants in Breast Cancer Cases: A Single-Center Experience

    DergiPark (Istanbul University), 2025

    Kaynak: OpenAlex

  22. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

    International Journal of Clinical Oncology, 2024

    DOI 10.1007/s10147-023-02460-5 PMID 38310597 6 atıf (Europe PMC) Kaynak: OpenAlex

  23. Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-81371-5 PMID 39616250 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  24. Screening for the Frequency of Fabry Disease in Patients Followed Up in the Nephrology Outpatient Clinic

    Turkish Journal of Nephrology, 2024

    DOI 10.5152/turkjnephrol.2024.23511 Açık erişimli tam metinKaynak: ORCID

  25. Treatment Strategies for Glioblastoma Multiforme: A Single Center Experience

    Journal of Oncological Science, 2024

    DOI 10.37047/jos.2023-98703 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  26. Neuroendocrine Differentiated Breast Cancer Cases: A Retrospective Analysis and Literature Review

    2021

    DOI 10.21203/rs.3.rs-433514/v1 Açık erişimli tam metinKaynak: ORCID

  27. Neuroendocrine Differentiated Breast Cancer Cases: A Retrospective Analysis and Literature Review

    Sisli Etfal Hastanesi tip bulteni, 2021

    DOI 10.14744/semb.2021.66503 PMID 35317367 7 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  28. Tükrük Bezi Tümörlerinde Kemoterapi

    2021

    Kaynak: OpenAlex

  29. Opere Over Kanseri Hastalarında Preoperatif Yüksek CA125 Değerinin Postoperatif Normal Sınırlara Dönmesinin Klinik Önemi

    Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi, 2020

    DOI 10.34087/cbusbed.743230 Kaynak: ORCID

  30. Preliminary study of serum Galectin-1 in breast cancer carcinogenesis [Izmir Oncology Group (IZOG) study].

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2020

    PMID 32521852 4 atıf (Europe PMC) Kaynak: ORCID

  31. Prognostic role of De Ritis and basal neutrophil to lymphocyte ratio in patients with advanced stage pancreatic cancer [Izmir Oncology Group (IZOG) Study].

    Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2020

    PMID 32521907 2 atıf (Europe PMC) Kaynak: ORCID

  32. Chemotherapy-induced sarcopenia in newly diagnosed cancer patients: Izmir Oncology Group (IZOG) study

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020

    DOI 10.1007/s00520-019-05165-6 PMID 31758325 13 atıf (Europe PMC) Kaynak: ORCID

  33. Preliminary study of serum Galectin-1 in breast cancer carcinogenesis [Izmir Oncology Group (IZOG) study]

    JOURNAL OF BUON, 2020

    Kaynak: ORCID

  34. Preliminary study of serum Galectin-1 in breast cancer carcinogenesis [Izmir Oncology Group (IZOG) study]

    Journal of B U on, 2020

    Kaynak: ORCID

  35. Prognostic role of De Ritis and basal neutrophil to lymphocyte ratio in patients with advanced stage pancreatic cancer [Izmir Oncology Group (IZOG) Study]

    JOURNAL OF BUON, 2020

    Kaynak: ORCID

  36. Prognostic role of De Ritis and basal neutrophil to lymphocyte ratio in patients with advanced stage pancreatic cancer [Izmir Oncology Group (IZOG) Study]

    Journal of B U on, 2020

    Kaynak: ORCID

  37. Prognostic value of De Ritis ratio (aspartate transaminase/alanine transaminase) in patients with non-metastatic colorectal carcinoma [izmir oncology group(IZOG) study].

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.e16114 Kaynak: ORCID

  38. The role of inflammation in adjuvant chemotherapy-induced sarcopenia (Izmir Oncology Group (IZOG) study)

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020

    DOI 10.1007/s00520-020-05477-y PMID 32335732 20 atıf (Europe PMC) Kaynak: ORCID

  39. Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The Izmir oncology group (IZOG) study

    Annals of Medical Research, 2020

    DOI 10.5455/annalsmedres.2019.12.862 Açık erişimli tam metinKaynak: OpenAlex

  40. Prognostic role of pretreatment de ritis and neutrophil to lymphocyte ratio in neuroendocrine carcinoma patients (Izmir oncology group study)

    Annals of Medical Research, 2020

    DOI 10.5455/annalsmedres.2020.01.057 Açık erişimli tam metinKaynak: OpenAlex

  41. ASSESMENT OF PROVEN INVASIVE FUNGAL SINUSITIS: A ONE-YEAR ONE-CENTER EXPERIENCE

    LEUKEMIA RESEARCH, 2015

    Kaynak: ORCID

  42. Predictive Factors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing 177Lu-PSMA-617 Radioligand Treatment

    Kaynak: ORCID